Diabnext Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

Diabnext General Information

Description

Developer of a digital diabetes management application designed to better manage pre-diabetes and diabetes patients. The company's application provides injection follow-ups, blood sugar level measurement, facilitates automated recording of insulin units and blood glucose levels and offers remote monitoring and coordination, enabling healthcare professionals to track and educate their patients more accurately, more efficiently and productively and diabetes patients to manage their disease by setting reminders to check their blood glucose and take medications.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • 10 rue Treilhard
  • 75008 Paris
  • France
+33 0
Primary Industry
Monitoring Equipment
Other Industries
Other Healthcare Technology Systems
Acquirer
Vertical(s)
Corporate Office
  • 10 rue Treilhard
  • 75008 Paris
  • France
+33 0

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Diabnext Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Diabnext‘s full profile, request access.

Request a free trial

Diabnext Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a digital diabetes management application designed to better manage pre-diabetes and diabetes patients. The
Monitoring Equipment
Paris, France
11 As of 2022

San Diego, CA
 

Malvern, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Diabnext Competitors (34)

One of Diabnext’s 34 competitors is GlySens, a Venture Capital-Backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GlySens Venture Capital-Backed San Diego, CA
LifeScan Formerly PE-Backed Malvern, PA
Ascensia Diabetes Care Formerly PE-Backed Basel, Switzerland
GlucoTrack Technologies Corporate Backed or Acquired Rutherford, NJ
DexCom Formerly VC-backed San Diego, CA
You’re viewing 5 of 34 competitors. Get the full list »

Diabnext Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Diabnext FAQs

  • When was Diabnext founded?

    Diabnext was founded in 2016.

  • Where is Diabnext headquartered?

    Diabnext is headquartered in Paris, France.

  • What is the size of Diabnext?

    Diabnext has 11 total employees.

  • What industry is Diabnext in?

    Diabnext’s primary industry is Monitoring Equipment.

  • Is Diabnext a private or public company?

    Diabnext is a Private company.

  • What is Diabnext’s current revenue?

    The current revenue for Diabnext is .

  • Who are Diabnext’s competitors?

    GlySens, LifeScan, Ascensia Diabetes Care, GlucoTrack Technologies, and DexCom are some of the 34 competitors of Diabnext.

  • When was Diabnext acquired?

    Diabnext was acquired on 16-Mar-2022.

  • Who acquired Diabnext?

    Diabnext was acquired by Glooko.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process